Selected Grants
A Global Phase 3 Open-Label Extension Study to Assess the Long-Term Safety, Tolerability, and Efficacy of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Clinical TrialPrincipal Investigator · Awarded by Avidity Biosciences · 2025 - 2028A Phase 3 Randomized, Double-Blind, Placebo[1]Controlled, Global Study to Evaluate the Efficacy and Safety of Intravenous AOC 1001 for the Treatment of Myotonic Dystrophy Type 1
Clinical TrialPrincipal Investigator · Awarded by Avidity Biosciences · 2024 - 2027Nerve Ultrasound for Diagnosis and Prognosis of GBS
ResearchPrincipal Investigator · Awarded by GBS/CIDP Foundation International · 2020 - 2023A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CROVALIMAB IN PATIENTS WITH GUILLAIN-BARRÉ SYND
Clinical TrialPrincipal Investigator · Awarded by Genetech · 2022 - 2023UCB-UNC Fellowship in Neurology Clinical Drug Development
Inst. Training Prgm or CMEFellow · Awarded by University of North Carolina - Chapel Hill · 2019 - 2021External Relationships
- Natus Medical Incorporated
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.